MindMaze Therapeutics Holding (XSWX:MMTX) Other Long Term Assets: CHF0.11 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MMTX MindMaze Therapeutics Holding SA XSWX:MMTX
4 GF Score
Price CHF0.16
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Other Long Term Assets?

MindMaze Therapeutics Holding XSWX:MMTX +3.67% 4 Other Long Term Assets is CHF0.11 Mil as of Dec. 2025. GuruFocus rates XSWX:MMTX with a GF Score™ of 4/100. The stock has 2 warning signs investors should review.

MindMaze Therapeutics Holding's other long-term assets for the quarter that ended in Dec. 2025 was CHF0.11 Mil.

MindMaze Therapeutics Holding's quarterly other long-term assets increased from . 20 (CHF0.00 Mil) to Dec. 2024 (CHF0.09 Mil) and increased from Dec. 2024 (CHF0.09 Mil) to Dec. 2025 (CHF0.11 Mil).

MindMaze Therapeutics Holding's annual other long-term assets increased from . 20 (CHF0.00 Mil) to Dec. 2024 (CHF0.09 Mil) and increased from Dec. 2024 (CHF0.09 Mil) to Dec. 2025 (CHF0.11 Mil).

MindMaze Therapeutics Holding Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding Other Long Term Assets Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
Other Long Term Assets
0.09 0.11

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
Other Long Term Assets 0.09 0.11
XSWX:MMTX
4GF Score
MindMaze Therapeutics Holding SA XSWX:MMTX
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of CHF0.11 Mil mean?
MindMaze Therapeutics Holding (XSWX:MMTX) has a Other Long Term Assets of CHF0.11 Mil as of Dec. 2025. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Other Long Term Assets too high?
MindMaze Therapeutics Holding's current Other Long Term Assets is CHF0.11 Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Other Long Term Assets compare to VRTX and REGN?
MindMaze Therapeutics Holding's Other Long Term Assets of CHF0.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Other Long Term Assets is CHF0.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Other Long Term Assets of CHF0.11 Mil. The current Other Long Term Assets is CHF0.11 Mil. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Other Long Term Assets is CHF0.11 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTXz:UK
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score

Get the complete analysis for XSWX:MMTX

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.16
Price